Odds of any acute cardiovascular event increased when compared with COVID-19 hospitalizations in boosted and unboosted individuals.

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

As of mid-May, this variant has been identified in nearly 11% of sequenced samples reported worldwide. The WHO has designated this variant as a “variant under monitoring,” and currently assesses the ...

The announcement bypassed the usual review by the CDC’s Advisory Committee on Immunization Practices, a group that typically meets to review data and offer guidance on who should get a vaccine.

ND0612 is an investigational drug-device therapy that provides a 24-hour continuous subcutaneous infusion of levodopa/carbidopa solution. The Food and Drug Administration (FDA) has accepted for review ...

To assess the safety and efficacy of IV ibuprofen in older adults, researchers conducted a post hoc subgroup analysis with data from 4 prospective clinical studies.

The trained AI model correctly detected 98 and 100% of body parts and eczema areas, respectively; across 220 test images. HealthDay News — An artificial intelligence (AI) 3-Item Severity (3IS) score ...

In a recent interview on NBC News’ "Meet the Press," Murthy said Congress has failed to act on what he described as a growing crisis.

“The FDA’s decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people ...

Findings seen for patients with extensive-stage small cell lung cancer, following standard induction therapy.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.